Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin Bcell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed,cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partialremission of disease in less than half percent of PEL patients.
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model / Romeo, Maria Anele; Focaccetti, Chiara; Arena, Andrea; Benedetti, Rossella; Di Crosta, Michele; Palumbo, Camilla; Gilardini Montani, Maria Saveria; Santarelli, Roberta; Gonnella, Roberta; D'Orazi, Gabriella; Bei, Roberto; Cirone, Mara. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - 42:2(2024). [10.1002/hon.3262]
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
Romeo, Maria Anele;Arena, Andrea;Benedetti, Rossella;Di Crosta, Michele;Gilardini Montani, Maria Saveria;Santarelli, Roberta;Gonnella, Roberta;Cirone, Mara
2024
Abstract
Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin Bcell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed,cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partialremission of disease in less than half percent of PEL patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Romeo_New-insights-Bortezomib_2024.pdf
Open Access dal 11/10/2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
339.22 kB
Formato
Adobe PDF
|
339.22 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
